Molecular hydrogen · graded by use, two uses
Molecular Hydrogen Water
Total and LDL Low-density lipoprotein cholesterol, the cholesterol fraction most closely tied to plaque in the arteries. cholesterol in adults with overweight, obesity or metabolic disorders.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
Compare this record with another, side by side →
How this letter has changedLatest: October 2026 · Corrected.
The record's only citation (Zanini et al., 2021; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 34601077) was a 40-person pilot that found no lipid or metabolic difference, while the evidence note claimed multiple positive trials and the flags claimed a meta-analysis nobody cited. The lipid claim now rests on the three meta-analyses that exist and disagree (Ye et al., 2026; PMID 41888952; Jamialahmadi et al., 2024; PMID 39839806; Todorovic et al., 2023; PMID 37259294), with the key 24-week trial's part-funding by the tablet maker and its lead author's industry consultancy stated beside the letter (LeBaron et al., 2020; PMID 32273740). Zanini 2021 is relabeled as a pilot null on the graded endpoint. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 32273740 PMID 34601077 PMID 37259294 PMID 39839806 PMID 41888952
Every change to a letter on this site is dated and published. The full evidence log →
Hydrogen water is water with extra hydrogen gas dissolved in it. In adults with weight or blood sugar problems, three reviews of small studies looked at cholesterol. The largest found total and LDL cholesterol a little lower, but by amounts its own authors called too small to matter. In people with mild COVID, it did not keep them from getting worse.
The C belongs to one of the two uses graded on this record. The other one carries its own letter.
As studied, and the trials
Mixed. Ye et al. (2026; PMID 41888952) pool 13 trials: total cholesterol about 7 mg/dL and LDL about 3 mg/dL lower, below the thresholds the authors consider meaningful. Jamialahmadi et al. (2024; PMID 39839806) pool 8 trials and find only triglycerides changed. Todorovic et al. (2023; PMID 37259294) pool 7 and find small to moderate reductions in all three, from a group that ran several of the trials. The key 24-week positive trial (LeBaron et al., 2020; PMID 32273740) was part-funded by the tablet maker, stated beside the letter. Small, inconsistent surrogate changes: C.
As studied, and the trials
Gaboreau et al. (J Clin Med, 2024; PMID 39124575), Hydro-COVID: a phase 3, triple-blind, placebo-controlled multicenter trial in primary care. Hydrogen-rich water twice daily for 21 days did not reduce clinical worsening at day 14 (46.1 against 43.5 percent, hazard ratio How often an event happened in the treated group compared with the control group over the same period. A ratio of 0.80 means 20 percent fewer events. 1.09). The largest hydrogen water trial on record, tested on its primary endpoint The one outcome a trial names in advance as its main test. Results on other outcomes carry less weight. without benefit: D on Route 2 Human randomized trials have been run and did not show benefit on the stated outcome. One of the two routes to the lowest letter on EBL's scale..
Read the grade that matches your goal. How EBL grades by use →
A letter describes the human evidence, not the product, the manufacturer, or the intervention's worth.
See the full evidence record →Funding: The single trial this Grade C for Total and LDL cholesterol in adults with overweight, obesity or metabolic disorders rests on was funded by the maker of the device it tested. The funder's role in design and analysis is not stated here, because the full trial report could not be read. The letter is what the trial supports under the grading rules; the funding is stated here so it can be weighed alongside it. Investigators: The single trial this Grade C for Total and LDL cholesterol in adults with overweight, obesity or metabolic disorders rests on was run by investigators employed by, founded by, or belonging to the organization that developed, sells or teaches the intervention (the lead author is affiliated with the Molecular Hydrogen Institute and reports consultancy fees from commercial entities regarding molecular hydrogen). The funder may read non-commercial; the people who ran the trial are part of the organization whose intervention they tested, which is stated here so it can be weighed alongside the letter.
Graded on Total and LDL cholesterol in adults with metabolic disorders (small, sub-threshold changes).
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C on blood lipids in adults with metabolic disorders. Three meta-analyses pool small randomized trials and disagree: the largest (Ye et al., 2026; PMID 41888952, 13 trials) finds total and LDL cholesterol lower by amounts its authors call below clinically meaningful thresholds, a second (Jamialahmadi et al., 2024; PMID 39839806) finds only triglycerides changed, and a third from a group that runs many of the trials (Todorovic et al., 2023; PMID 37259294) finds small to moderate reductions. The record's original citation, a 40-person pilot in adults aged 70 and over (Zanini et al., 2021; PMID 34601077), found no lipid or metabolic difference. The key positive 24-week trial was part-funded by the tablet maker (LeBaron et al., 2020; PMID 32273740). Small, inconsistent, clinically trivial surrogate changes are C. A phase 3 trial of 675 outpatients with COVID-19 found no reduction in clinical worsening (Gaboreau et al., 2024; PMID 39124575), graded D on Route 2 as a separate use.
WHAT THIS GRADE DOES NOT COVERinhaled hydrogen, graded separately; any clinical outcome; telomere length or other aging markers, measured in one pilot without replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away.; and hydrogen concentration at the point of use, which most commercial products do not verify.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Each use, with its trials
This record carries a separate letter for each thing it has been measured on. The headline grade is the best of them, and it does not transfer to the others.
Mixed. Ye et al. (2026; PMID 41888952) pool 13 trials: total cholesterol about 7 mg/dL and LDL about 3 mg/dL lower, below the thresholds the authors consider meaningful. Jamialahmadi et al. (2024; PMID 39839806) pool 8 trials and find only triglycerides changed. Todorovic et al. (2023; PMID 37259294) pool 7 and find small to moderate reductions in all three, from a group that ran several of the trials. The key 24-week positive trial (LeBaron et al., 2020; PMID 32273740) was part-funded by the tablet maker, stated beside the letter. Small, inconsistent surrogate changes: C.
Gaboreau et al. (J Clin Med, 2024; PMID 39124575), Hydro-COVID: a phase 3, triple-blind, placebo-controlled multicenter trial in primary care. Hydrogen-rich water twice daily for 21 days did not reduce clinical worsening at day 14 (46.1 against 43.5 percent, hazard ratio 1.09). The largest hydrogen water trial on record, tested on its primary endpoint without benefit: D on Route 2.
The evidence, in fullSix papers, each linked to its PubMed record.
Ye et al. (Diabetol Metab Syndr, 2026; PMID 41888952): 13 randomized trials, 757 adults with overweight or obesity; total cholesterol 6.7 mg/dL and LDL 3.2 mg/dL lower than control, HDL slightly lower, triglycerides unchanged, effects the authors describe as below thresholds meaningful for cardiovascular risk. Jamialahmadi et al. (Int J Endocrinol Metab, 2024; PMID 39839806): 8 trials, 357 patients with metabolic disorders; only triglycerides fell, with confidence intervals The range the true effect probably falls in. A wide interval means the estimate is uncertain. for total and LDL cholesterol crossing zero. Todorovic et al. (Pharmaceuticals, 2023; PMID 37259294): 7 trials; small to moderate reductions in total cholesterol, LDL and triglycerides, from the Novi Sad group that runs several of the pooled trials. LeBaron et al. (Diabetes Metab Syndr Obes, 2020; PMID 32273740): 60 adults with metabolic syndrome, 24 weeks of high-concentration hydrogen water; cholesterol, glucose and HbA1c A blood test that reflects average blood sugar over the previous two to three months. lower than placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received.; part-funded by the maker of the tablets tested, with the lead author reporting consultancy and speaking fees from commercial entities regarding molecular hydrogen, stated beside the letter. Zanini et al. (Experimental Gerontology, 2021; PMID 34601077): 40-person pilot in adults aged 70 and over, 6 months; telomere length, a DNA methylation marker, brain metabolites and one physical test changed, lipid and metabolic outcomes did not, so it does not support the graded endpoint. Gaboreau et al. (J Clin Med, 2024; PMID 39124575), Hydro-COVID: phase 3, triple-blind, 675 primary care outpatients with mild to moderate COVID-19; hydrogen-rich water twice daily for 21 days did not reduce clinical worsening at day 14 (46.1 against 43.5 percent), graded D on Route 2 as a separate use. Grade C: small, inconsistent, clinically trivial surrogate changes. Inhaled molecular hydrogen is a separate intervention, graded separately.
HsCRP and 8-isoprostane at baseline and 8 weeks for oxidative stress applications. Fasting glucose at baseline and 12 weeks for metabolic applications. Hydrogen concentration in solution must be verified at point of use: most commercial H2 water products degas rapidly and deliver negligible active hydrogen by the time of consumption.
Evidence notes: meta-analysis, randomized trial
Endpoint graded: Total and LDL cholesterol in adults with metabolic disorders (small, sub-threshold changes) (surrogate)
Last reviewed: July 2026
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Primary evidenceSix papers, each linked to its PubMed record.
Ye et al. (Diabetol Metab Syndr, 2026; PMID 41888952): 13 randomized trials, 757 adults with overweight or obesity; total cholesterol 6.7 mg/dL and LDL 3.2 mg/dL lower than control, HDL slightly lower, triglycerides unchanged, effects the authors describe as below thresholds meaningful for cardiovascular risk. Jamialahmadi et al. (Int J Endocrinol Metab, 2024; PMID 39839806): 8 trials, 357 patients with metabolic disorders; only triglycerides fell, with confidence intervals for total and LDL cholesterol crossing zero. Todorovic et al. (Pharmaceuticals, 2023; PMID 37259294): 7 trials; small to moderate reductions in total cholesterol, LDL and triglycerides, from the Novi Sad group that runs several of the pooled trials. LeBaron et al. (Diabetes Metab Syndr Obes, 2020; PMID 32273740): 60 adults with metabolic syndrome, 24 weeks of high-concentration hydrogen water; cholesterol, glucose and HbA1c lower than placebo; part-funded by the maker of the tablets tested, with the lead author reporting consultancy and speaking fees from commercial entities regarding molecular hydrogen, stated beside the letter. Zanini et al. (Experimental Gerontology, 2021; PMID 34601077): 40-person pilot in adults aged 70 and over, 6 months; telomere length, a DNA methylation marker, brain metabolites and one physical test changed, lipid and metabolic outcomes did not, so it does not support the graded endpoint. Gaboreau et al. (J Clin Med, 2024; PMID 39124575), Hydro-COVID: phase 3, triple-blind, 675 primary care outpatients with mild to moderate COVID-19; hydrogen-rich water twice daily for 21 days did not reduce clinical worsening at day 14 (46.1 against 43.5 percent), graded D on Route 2 as a separate use. Grade C: small, inconsistent, clinically trivial surrogate changes. Inhaled molecular hydrogen is a separate intervention, graded separately.
Products carry no letter. The letter belongs to the therapy as the trials studied it, and no trial tested these products unless the entry says so. Listed alphabetically; payment does not affect order.
Japanese-manufactured H₂ water generator. Japan has the most rigorous H₂ research ecosystem. Countertop unit producing high-concentration H₂ water consistently.
The C rests on meta-analyses of small trials in which adults with overweight, obesity or metabolic disorders drank hydrogen-rich water daily for 4 to 24 weeks, at doses that varied; the 24-week trial gave more than 5.5 millimoles of hydrogen a day, from tablets. The seller states this unit reaches up to about 1.6 ppm, which EBL has not measured; at that concentration 5.5 millimoles is about 7 liters of water. The bundle's inhalation kit is a separate therapy, inhaled hydrogen, graded on its own.
This page carries a letter. EBL takes no commission, referral fee or payment of any kind on anything it grades. No letter has been bought and none is for sale. Products listed under this modality may be commercial partners, and their purchase links may earn EBL a commission. Those products carry no letter of their own, every relationship is disclosed beside the link, and where a product does not deliver what the trials tested, this page says so regardless of who pays.
How this is enforced
That is not a promise, it is a build condition. Two checks run on every deploy: one refuses to publish if a commission is claimed on anything graded, the other refuses if a page names a commercial relationship that is not declared in the register. If either fails, this page does not go live. You can read how the checks work, and what they do not cover, on the evidence integrity page.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc.. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
(hydrogen-rich water[tiab] OR hydrogen water[tiab]) AND (lipid*[tiab] OR cholesterol[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt])Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →